Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 4
2020 1
2021 2
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

12 results
Results by year
Filters applied: . Clear all
Page 1
Clonal replacement of tumor-specific T cells following PD-1 blockade.
Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, McNamara KL, Granja JM, Sarin KY, Brown RA, Gupta RK, Curtis C, Bucktrout SL, Davis MM, Chang ALS, Chang HY. Yost KE, et al. Among authors: bucktrout sl. Nat Med. 2019 Aug;25(8):1251-1259. doi: 10.1038/s41591-019-0522-3. Epub 2019 Jul 29. Nat Med. 2019. PMID: 31359002 Free PMC article.
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
O'Hara MH, O'Reilly EM, Varadhachary G, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Mick R, Gherardini PF, Kitch LJ, Xu J, Samuel T, Karakunnel J, Fairchild J, Bucktrout S, LaVallee TM, Selinsky C, Till JE, Carpenter EL, Alanio C, Byrne KT, Chen RO, Trifan OC, Dugan U, Horak C, Hubbard-Lucey VM, Wherry EJ, Ibrahim R, Vonderheide RH. O'Hara MH, et al. Among authors: bucktrout s. Lancet Oncol. 2021 Jan;22(1):118-131. doi: 10.1016/S1470-2045(20)30532-5. Lancet Oncol. 2021. PMID: 33387490 Clinical Trial.
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.
Padrón LJ, Maurer DM, O'Hara MH, O'Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Yu JX, Pfeiffer SM, Spasic M, Xu J, Gherardini PF, Karakunnel J, Mick R, Alanio C, Byrne KT, Hollmann TJ, Moore JS, Jones DD, Tognetti M, Chen RO, Yang X, Salvador L, Wherry EJ, Dugan U, O'Donnell-Tormey J, Butterfield LH, Hubbard-Lucey VM, Ibrahim R, Fairchild J, Bucktrout S, LaVallee TM, Vonderheide RH. Padrón LJ, et al. Among authors: bucktrout s. Nat Med. 2022 Jun;28(6):1167-1177. doi: 10.1038/s41591-022-01829-9. Epub 2022 Jun 3. Nat Med. 2022. PMID: 35662283 Free PMC article. Clinical Trial.
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.
Friedman CF, Spencer C, Cabanski CR, Panageas KS, Wells DK, Ribas A, Tawbi H, Tsai K, Postow M, Shoushtari A, Chapman P, Karakunnel J, Bucktrout S, Gherardini P, Hollmann TJ, Chen RO, Callahan M, LaVallee T, Ibrahim R, Wolchok J. Friedman CF, et al. Among authors: bucktrout s. J Immunother Cancer. 2022 Jan;10(1):e003853. doi: 10.1136/jitc-2021-003853. J Immunother Cancer. 2022. PMID: 35074903 Free PMC article. Clinical Trial.
Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR.
Bayless NL, Bluestone JA, Bucktrout S, Butterfield LH, Jaffee EM, Koch CA, Roep BO, Sharpe AH, Murphy WJ, Villani AC, Walunas TL. Bayless NL, et al. Among authors: bucktrout s. J Immunother Cancer. 2021 Sep;9(9):e002627. doi: 10.1136/jitc-2021-002627. J Immunother Cancer. 2021. PMID: 34479924 Free PMC article. Review.
Characterization and Comparison of GITR Expression in Solid Tumors.
Vence L, Bucktrout SL, Fernandez Curbelo I, Blando J, Smith BM, Mahne AE, Lin JC, Park T, Pascua E, Sai T, Chaparro-Riggers J, Subudhi SK, Scutti JB, Higa MG, Zhao H, Yadav SS, Maitra A, Wistuba II, Allison JP, Sharma P. Vence L, et al. Among authors: bucktrout sl. Clin Cancer Res. 2019 Nov 1;25(21):6501-6510. doi: 10.1158/1078-0432.CCR-19-0289. Epub 2019 Jul 29. Clin Cancer Res. 2019. PMID: 31358539 Free PMC article.
Advancing T cell-based cancer therapy with single-cell technologies.
Bucktrout SL, Banovich NE, Butterfield LH, Cimen-Bozkus C, Giles JR, Good Z, Goodman D, Jonsson VD, Lareau C, Marson A, Maurer DM, Munson PV, Stubbington M, Taylor S, Cutchin A. Bucktrout SL, et al. Nat Med. 2022 Sep;28(9):1761-1764. doi: 10.1038/s41591-022-01986-x. Nat Med. 2022. PMID: 36127419 No abstract available.
GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma.
van Beek AA, Zhou G, Doukas M, Boor PPC, Noordam L, Mancham S, Campos Carrascosa L, van der Heide-Mulder M, Polak WG, Ijzermans JNM, Pan Q, Heirman C, Mahne A, Bucktrout SL, Bruno MJ, Sprengers D, Kwekkeboom J. van Beek AA, et al. Among authors: bucktrout sl. Int J Cancer. 2019 Aug 15;145(4):1111-1124. doi: 10.1002/ijc.32181. Epub 2019 Feb 27. Int J Cancer. 2019. PMID: 30719701 Free PMC article.
Model-Based Characterization of the Pharmacokinetics, Target Engagement Biomarkers, and Immunomodulatory Activity of PF-06342674, a Humanized mAb Against IL-7 Receptor-α, in Adults with Type 1 Diabetes.
Williams JH, Udata C, Ganguly BJ, Bucktrout SL, Joh T, Shannon M, Wong GY, Levisetti M, Garzone PD, Meng X. Williams JH, et al. Among authors: bucktrout sl. AAPS J. 2020 Jan 3;22(2):23. doi: 10.1208/s12248-019-0401-3. AAPS J. 2020. PMID: 31900603 Free PMC article. Clinical Trial.
12 results